HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $40 price target.
July 26, 2024 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $40 price target.
The reiteration of a Buy rating and the maintenance of a $40 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100